Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Instil Bio Reports $4.2 Million Third-Quarter Net Loss

None

Instil Bio (TIL) reported a third-quarter 2026 net loss of $4.2 million, or $0.62 per basic and diluted share, compared with a $13.6 million net loss in the prior-year quarter.

The biotechnology company reported $67.1 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments as of September 30, 2026, and said the balance is expected to fund its operating plan through 2027.

  • Research and development expense was $0.2 million in the quarter, versus $9.1 million a year earlier.
  • General and administrative expense was $5.8 million, compared with $6.3 million in the prior-year quarter.
  • Other rental income totaled $2.7 million, while interest expense was $1.6 million.
  • Instil said it corrected prior-period information related to property taxes, tenant reimbursements and other immaterial errors; no prior filing is being amended.
EARLY ACCESS
Receive TIL Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$TIL Hedge Fund Activity

We have seen 9 institutional investors add shares of $TIL stock to their portfolio, and 18 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles